IFNG and neoplasm: This observed tumor weight difference translates into functional relevance based on CD4 IFNγ levels, and hence, we categorized the CD4 IFNγ high expression group as responders and the CD4 IFNγ low expression group as non-responders to the ITI-1001 treatment.